Is Sermorelin Legal? What the Regulatory Record Actually Shows

By Victor Björk

Sermorelin occupies a legally precarious position in the United States market, and the peptide forums that cite its non-scheduled status as proof of broad legality are confusing two entirely different regulatory questions. Whether a compound is a controlled substance and whether it can be lawfully manufactured, distributed, and sold are separate determinations. The regulatory record on sermorelin is specific, documented, and considerably less permissive than its current clinical footprint suggests.

The Regulatory Spine: What the FDA Record Says About Sermorelin

Sermorelin acetate was FDA-approved as Geref in 1990, but the approved indication was narrow: diagnostic testing of growth hormone secretion in children with suspected GH deficiency. A 2024 review in Biomolecules covering FDA-approved peptide analogues in the GHRH class confirms this developmental history, situating sermorelin’s authorization within the diagnostic rather than the therapeutic category. [1] That distinction matters enormously for what came next.

Sereno’s voluntary market withdrawal of Geref in 2008 removed the only FDA-approved sermorelin product from commerce. After that withdrawal, sermorelin migrated almost entirely into the compounding pharmacy channel. Its continued clinical use now rests not on an approved New Drug Application but on compliance with 503A and 503B compounding regulations, a structurally different and considerably more fragile legal foundation.

One fact gets repeated constantly to reassure patients and prescribers: sermorelin is not a scheduled controlled substance under the Controlled Substances Act. True, and almost beside the point. Scheduling status addresses abuse potential and DEA jurisdiction; it says nothing about whether a drug can be lawfully compounded, marketed, or sold.

What the 2023 FDA Bulks List Decision Actually Did

The 2023 FDA decision on the 503B bulk drug substances list is the regulatory event that most practitioners in the anti-aging and sports medicine space have either misread or ignored entirely. The FDA declined to include sermorelin on the 503B bulks list, citing the absence of sufficient clinical evidence supporting sermorelin’s use in the indications for which it is currently compounded, primarily adult anti-aging and body composition applications. The practical consequence is that outsourcing facilities operating under 503B cannot compound sermorelin for distribution to clinics without patient-specific prescriptions.

This matters because a substantial portion of the clinic-based sermorelin market operates on the 503B model: a facility compounds sermorelin in bulk, ships it to a clinic, and the clinic dispenses it across a patient population. That supply chain is now in direct conflict with the FDA’s 2023 determination.

503A compounding pharmacies, which fill prescriptions for individual identified patients, operate under a different statutory framework. They may still compound sermorelin provided a valid patient-specific prescription exists and the compound has not been added to the FDA’s list of drugs withdrawn for safety or efficacy reasons. The 503A pathway remains open, but it is narrower than the market currently treats it, and it is not permanent.

The practical reality: Large-scale, anticipatory compounding of sermorelin for distribution to clinics without patient-specific prescriptions became legally untenable after the 2023 guidance. Clinics sourcing sermorelin this way are operating outside the rules, not in a gray area.

The Clinical Evidence Sermorelin’s Legal Status Rests On, and Doesn’t

The evidentiary gap that drove the 503B exclusion is real and worth examining directly, because the FDA’s decision did not come from bureaucratic indifference to the compound. It came from the absence of trials that would actually support the indications being claimed.

The original Geref approval rested on sermorelin’s diagnostic utility in pediatric GH deficiency testing, not on any demonstrated benefit for adult GH secretagogue therapy. The human trial base for adult indications is thin to the point of being almost nonexistent at the Phase III level.

What the existing trials actually show:

• The Walker et al. 2004 study in the Journal of the American Geriatrics Society, which is frequently cited in compounding contexts, enrolled 89 older adults and reported increases in IGF-1 levels and improvements in sleep quality following sermorelin administration. It lacked a pre-specified primary endpoint powered for body composition outcomes, the very outcomes being marketed. Citing this trial as evidence for anti-aging body composition benefits is a significant overreach of what the data support.

• No Phase III randomized controlled trial has evaluated sermorelin for adult growth hormone deficiency or anti-aging indications with a sample size sufficient to support an NDA submission. This is not a minor gap. It is the central one.

Sermorelin’s mechanism is pharmacologically interesting: as a GHRH(1-29) analogue, it stimulates endogenous GH release rather than replacing GH directly. [2] Proponents argue this produces a more physiologic pulsatile GH profile than exogenous recombinant human GH, and the argument is not unreasonable on mechanistic grounds. A plausible mechanism, though, is not a clinical trial, and the FDA does not approve drugs on the basis of physiological elegance.

What the Evidence Does Not Support

The existing human trials for adult sermorelin use are predominantly open-label, short-duration studies with surrogate endpoints, IGF-1 elevation rather than fracture reduction, cardiovascular outcomes, or mortality. Surrogate endpoints are acceptable as early-phase signals; they are not acceptable as the sole basis for long-term clinical use in healthy adults.

Long-term safety data for sermorelin in adults are essentially absent. The approved pediatric indication involved short diagnostic dosing, not the months-long subcutaneous injection regimens that anti-aging clinics currently prescribe. These are not equivalent exposures, and treating them as equivalent is a clinical error.

The oncologic risk question deserves particular attention. Chronically elevated IGF-1 from GH secretagogue use carries a theoretical cancer risk that has not been formally evaluated for sermorelin in long-term human trials. A 2018 review in Sexual Medicine Reviews concluded that few long-term, rigorously controlled studies have examined GH secretagogue safety, and specifically called for future evaluation of cancer incidence and mortality with long-term use. [3] That call has not been answered for sermorelin. Prescribers offering months of sermorelin therapy to healthy adults are doing so without any long-term safety data to stand on.

Where Sermorelin Sits Against the Broader GH Secretagogue Literature

The comparison to tesamorelin is instructive and, for sermorelin advocates, uncomfortable. Tesamorelin is a GHRH analogue with a trans-3-hexenoic acid modification that achieved FDA approval in 2010 for HIV-associated lipodystrophy, based on two Phase III RCTs. A 2026 review in the International Journal of Molecular Sciences confirms that this class of peptide drugs can clear the regulatory bar when adequately studied. [4] Tesamorelin was studied; sermorelin, for the indications being marketed today, was not.

The contrast reflects the difference between a sponsor who ran the trials and one who never did. The GHRH secretagogue class is not inherently unapprovable for adult indications, sermorelin simply has no sponsor willing to generate the evidence that approval requires.

Meanwhile, ipamorelin and CJC-1295, two GH secretagogues widely co-administered with sermorelin in compounding practice, received a more restrictive outcome than sermorelin in 2023: placement on the FDA’s list of bulk drug substances that may not be compounded under either 503A or 503B. Sermorelin’s current 503A availability looks relatively permissive only by comparison to compounds that have been explicitly prohibited, which is a poor standard for “clearly permitted.”

What Actually Changes for Prescribers and Patients

For physicians prescribing through 503A pharmacies: The current position is legally defensible for individual patient prescriptions with documented clinical need, but it is not legally secure. The FDA retains authority to add sermorelin to its list of drugs that may not be compounded, and the 2023 bulks list decision signals an agency actively reviewing this class. Prescribers should not mistake the absence of a prohibition for the presence of approval.

For clinics sourcing from 503B outsourcing facilities: The 2023 determination makes bulk compounding without patient-specific prescriptions a direct regulatory violation, not a gray-area risk. Enforcement exposure is real.

For patients purchasing from online vendors outside the US compounding framework: These products carry no regulatory oversight of purity, potency, or sterility, a risk that exists entirely independently of the scheduling question that peptide forums treat as the only relevant legal consideration. An unscheduled compound manufactured by an unregulated overseas supplier is not a safe compound; it is an uncharacterized one.

The Regulatory and Clinical Developments That Will Settle This

The FDA’s ongoing review of the 503A bulk drug substances list will determine whether sermorelin retains its current compoundable status or follows ipamorelin and CJC-1295 onto the prohibited list. That review is active, and the direction of travel is not encouraging for compounded peptides as a category.

What would actually stabilize sermorelin’s legal position is an IND filing and a properly powered Phase III trial for an adult indication. As of the most recent public ClinicalTrials.gov records, no sponsor has filed to study sermorelin for adult GH deficiency or age-related GH decline. The evidentiary gap that drove the 503B exclusion is not being closed. If the FDA moves sermorelin to the 503A prohibited list, the only legal path to patient access in the United States would be through a new NDA or compassionate use, effectively ending its current role in anti-aging medicine.

The question the peptide community keeps avoiding is not whether sermorelin is scheduled. It is whether anyone is going to do the work that would make its use genuinely lawful and genuinely safe. So far, no one has.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.

References

1. Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms.. Biomolecules, 2024.

2. The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.. British journal of pharmacology, 2025.

3. The Safety and Efficacy of Growth Hormone Secretagogues.. Sexual medicine reviews, 2018.

4. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.. International journal of molecular sciences, 2026.